NASDAQ:BDTX Black Diamond Therapeutics Q1 2026 Earnings Report $1.66 0.00 (0.00%) Closing price 06/18/2026 04:00 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 06/18/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Black Diamond Therapeutics EPS ResultsActual EPS-$0.16Consensus EPS -$0.18Beat/MissBeat by +$0.02One Year Ago EPSN/ABlack Diamond Therapeutics Revenue ResultsActual RevenueN/AExpected Revenue$25.00 millionBeat/MissN/AYoY Revenue GrowthN/ABlack Diamond Therapeutics Announcement DetailsQuarterQ1 2026Date5/7/2026TimeAfter Market ClosesConference Call DateThursday, May 7, 2026Conference Call Time7:00AM ETUpcoming EarningsBlack Diamond Therapeutics' Q2 2026 earnings is estimated for Thursday, August 6, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)SEC FilingEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Black Diamond Therapeutics Earnings HeadlinesWedbush Remains a Buy on Black Diamond Therapeutics (BDTX)June 4, 2026 | theglobeandmail.comBlack Diamond Therapeutics, Inc.May 24, 2026 | edition.cnn.comIs SpaceX really worth 1.78 Trillion?With SpaceX approaching a near-$2 trillion valuation, most investors are focused on the IPO itself - but analyst Lance Ippolito says the real opportunity is elsewhere. He's identified 5 dirt-cheap stocks at the forefront of this mega-IPO, including a space ticker that Goldman Sachs, BlackRock, and Morgan Stanley are all buying, a rare resource miner Elon's entire empire depends on, and the chip supplier Starlink satellites can't function without. Access his free SpaceX Investing Blackbook before IPO day arrives.June 19 at 1:00 AM | InvestPub (Ad)Black Diamond Therapeutics to Participate in Jefferies Global Healthcare ConferenceMay 22, 2026 | globenewswire.comBlack Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical MutationsMay 21, 2026 | globenewswire.comBlack Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLCMay 19, 2026 | globenewswire.comSee More Black Diamond Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email. Email Address About Black Diamond TherapeuticsBlack Diamond Therapeutics (NASDAQ:BDTX) is a precision oncology company focused on the discovery and development of small-molecule therapies that selectively target oncogenic proteins bearing tumor-driving mutations. Leveraging its proprietary Genetic Defined Allosteric (GDA) therapeutic platform, the company aims to identify unique allosteric binding sites in mutant proteins and engineer highly selective inhibitors. Headquartered in Cambridge, Massachusetts, Black Diamond applies structure-based drug design and molecular modeling to advance personalized cancer treatments. The company’s development pipeline includes lead candidate BDTX-189, an allosteric inhibitor of mutant HER2, as well as programs directed at clinically relevant EGFR and KRAS mutations. Black Diamond’s approach seeks to overcome resistance mechanisms that often limit the efficacy of existing therapies by focusing on mutation-specific vulnerabilities. Early-stage clinical trials for BDTX-189 are evaluating safety, pharmacokinetics, and anti-tumor activity in patients whose tumors harbor HER2 alterations. Founded in 2019 and listed on the Nasdaq under the ticker BDTX, Black Diamond Therapeutics combines scientific expertise with experience drawn from leading biopharmaceutical organizations. The company collaborates with academic centers and research institutions to advance its pipeline and is committed to delivering next-generation precision medicines to oncology patients worldwide.View Black Diamond Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Satellogic Is Tiny But Its Revenue Growth Is Hard to IgnoreWhy Kroger’s Pullback Could Be a Gift for Patient InvestorsCredo Technologies Accelerates AI—Its Stock Price Will FollowWhy Palantir’s Google Cloud Deal Could Change the DebateAmerican Eagle’s Q1 Beat Leaves Investors With a Bigger QuestionCarMax In Reverse? Why You Should Buy Now Before the Big Catalysts EmergeJabil Just Gave Investors a Stronger Reason to Buy the Dip Upcoming Earnings FedEx (6/23/2026)Micron Technology (6/24/2026)NIKE (6/30/2026)PepsiCo (7/9/2026)Delta Air Lines (7/9/2026)Fastenal (7/13/2026)Bank of America (7/14/2026)The Goldman Sachs Group (7/14/2026)JPMorgan Chase & Co. (7/14/2026)Wells Fargo & Company (7/14/2026) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
